Blog Posts

active

Back to All Blog Posts
Clear Cell Sarcoma

Clear Cell Sarcoma BigData – Drug Discovery: $470,154 annually for 2 years

cc-TDI November 28, 2018

Clear Cell Sarcoma (CCS) is a very rare soft tissue of children and adults. The underlying clinical problem is that only surgery is curative: chemotherapy and radiation are ineffective. Relapse with metastases results in a significant unmet clinical need because surgery is not possible and effective targeted therapies have not yet been developed. To meet this clinical need by developing new therapies, the biology of CCS needs to be taken into consideration: not only is the EWSR1-ATF1 chimeric transcription factor/fusion gene present, but cooperating mutations may also be present.

CureFast: creating a Legacy by accelerating Childhood Cancer Research

cc-TDI November 28, 2018

We propose to address gaps in basic and translational research by improving model systems for pediatric diseases. To this end, we have developed a Legacy Gift (research autopsy) program called the Cancer Registry for Familial and Sporadic Tumors (CUREfast) to enable parents of children with cancer to donate tumor tissue to the research community.

Clear Cell Sarcoma

Clear Cell Sarcoma BigData – Drug Discovery: $470,154 annually for 2 years

cc-TDI November 28, 2018

Clear Cell Sarcoma (CCS) is a very rare soft tissue of children and adults. The underlying clinical problem is that only surgery is curative: chemotherapy and radiation are ineffective. Relapse with metastases results in a significant unmet clinical need because surgery is not possible and effective targeted therapies have not yet been developed. To meet this clinical need by developing new therapies, the biology of CCS needs to be taken into consideration: not only is the EWSR1-ATF1 chimeric transcription factor/fusion gene present, but cooperating mutations may also be present.

CureFast: creating a Legacy by accelerating Childhood Cancer Research

cc-TDI November 28, 2018

We propose to address gaps in basic and translational research by improving model systems for pediatric diseases. To this end, we have developed a Legacy Gift (research autopsy) program called the Cancer Registry for Familial and Sporadic Tumors (CUREfast) to enable parents of children with cancer to donate tumor tissue to the research community.

Navigation

Menu

Contact

More Information

EIN: 46-5759569

cc-TDI is a qualified 501(c)(3) charitable organization registered with the IRS
(consult with a CPA regarding specific tax implications)

 

Copyright 2019 – Children’s Cancer Therapy Development Institute

Close Menu